MBRX — Moleculin Biotech Share News
0.000.00%
Last trade - 00:00Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Moleculin Biotech Reports Second Quarter 2026 Financial Results And Highlights Continued Advancement Of Pivotal Miracle Trial
Moleculin Biotech expects cash position to fund operations into Q1 2027
Moleculin Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Moleculin Biotech Inc expected to post a loss of $1.54 a share - Earnings Preview
NASDAQ RESUMED AT 10:28 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:23 AM
NASDAQ RESUMED AT 10:22 AM
Brief: Moleculin Prices $9.30 Million Public Offering Of Shares And Warrants At $0.75 Per Share
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:12 AM
Brief: Moleculin’S Miracle R/R Aml Trial Reports Positive Interim Data With 37% Blinded Crc In Venetoclax-Failed Patients
Moleculin Biotech Q1 net loss widens as R&D costs rise
Brief: Moleculin Biotech Inc - To Unblind Miracle Trial Data Before June 30, 2026 - SEC Filing
Brief: Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)